Preclinical Indication Screening

LIDE’s Functional Diagnosis platform helps drug R&D companies overcome two primary challenges.

  1. Evaluating the best indications for promising compounds
  2. Identifying companion diagnosis for recruitment strategies

Indication Screening with MiniPDX®:
While LIDE offers standard in-vitro and in-vivo screening studies, we also recommend adding our MiniPDX® Mouse Trial as part of the validation process before more costly investments in complex in-vivo studies. 

  PDX MiniPDX 3D cells or Organoids
Study Type In-vivo In-vivo In-vitro
Study Length 4-6 months 7 days 2-8 weeks
Cost High Low Low
Predictive Power 89% 82%* TBD
Primary Benefit Gold standard validation for IND application Predictive power of PDX but shorter turnaround time Better representation of natural tumor environments vs 2D cell cultures

Table: Comparison of PDX, Organoids and MiniPDX® technologies
*by calculation here.

LIDE is participating in a real-world-evidence project across hospitals all over China that will eventually reach 10,000+ patients. This opportunity provides LIDE access to fresh tumor samples, many with special genetic alterations or drug resistance that is critical for validating new drug candidates.

By leveraging MiniPDX® technology and LIDE’s growing tissue library, drug companies can quickly identify or further evaluate potential indications, for a fraction of the cost and time required of PDX studies.

 

Fig. LIDE Functional Diagnosis platform offering indication screening and bio-marker determination.
Fig. LIDE Functional Diagnosis platform offering indication screening and bio-marker determination.

 

 

Read a Functional Diagnosis case study.

Download our MiniPDX fact sheet